Update Alert 5: Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults
- PMID: 33105094
- PMCID: PMC7596735
- DOI: 10.7326/L20-1293
Update Alert 5: Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults
Conflict of interest statement
Comment on
-
Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults: A Living Systematic Review.Ann Intern Med. 2020 Aug 4;173(3):195-203. doi: 10.7326/M20-1515. Epub 2020 May 15. Ann Intern Med. 2020. Update in: Ann Intern Med. 2021 Feb;174(2):W25-W29. doi: 10.7326/L20-1446. Update in: Ann Intern Med. 2021 Jun;174(6):W54-W55. doi: 10.7326/L21-0223. PMID: 32422062 Free PMC article. Updated.
References
-
- Adrish M, Chilimuri S, Sun H, et al. The association of renin-angiotensin-aldosterone system inhibitors with outcomes among a predominantly ethnic minority patient population hospitalized with COVID-19: the Bronx experience. Cureus. 2020;12:e10217. [PMID: 32905551] doi:10.7759/cureus.10217 - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous